Skip to main content

Enanta Pharmaceuticals, Inc.

corporate_fare Company Profile

Enanta Pharmaceuticals, Inc.

ENTA·NASDAQ·Life Sciences·CIK 0001177648

Enanta Pharmaceuticals, Inc. is a biotechnology company that uses a chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs, with an emphasis on viral infections and immunological diseases. In virology, Enanta discovered glecaprevir, the second of two antiviral protease inhibitors developed through its collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's leading brand of direct-acting antiviral (DAA) combination treatment for HCV, marketed under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir) since 2017 for the treatment of chronic HCV. MAVYRET®/MAVIRET® were also approved as the first and only treatments for acute HCV infection in the United States and the European Union in June 2025 and June 2026, respectively, as well as in several other countries including Canada and Australia. Enanta's active development programs in virology are focused on respiratory syncytial virus (RSV), the most common cause of bronchiolitis and pneumonia and a leading cause of U.S. hospitalization in young children and a significant cause of respiratory illness in older adults. Populations at high risk for severe RSV infection include infants and young children, adults older than 65 years of age, and those with comorbidities such as chronic heart or lung disease, diabetes, kidney disease, immunodeficiency and others. Estimates from the United States Centers for Disease Control and Prevention (CDC) for the 2024-2025 RSV season indicate that RSV led to up to 6.8 million outpatient visits, approximately 370,000 hospitalizations, and up to 24,000 deaths in the United States. Enanta estimates a global market opportunity of between $2.5 billion and $3.5 billion for an oral RSV antiviral for children and all high-risk adults, with a potential total addressable population of up to 4 million patients in the United States.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ENTA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Enanta Pharmaceuticals Seeks Shareholder Approval for Significant Equity Plan Expansion

Financial Snapshot

Fiscal year ended September 30, 2026
Revenue
$63M
Net Income
-$68.25M
Diluted EPS
-$2.35
Op. Cash Flow
-$42.56M
Free Cash Flow
-$42.77M
Operating Income
-$62.38M
Cash & Equivalents
$20.27M
Debt / Equity
0.00×
Net Margin
-108.3%
Shares Outstanding
29.14M sh
Source: 10-K · filed 2026-11-18 · accession 0001193125-26-466170
$7.62
52-week range · as of 2026-11-18 $7.62 – $17.15
Market cap
$222.19M
Volume
457.6K (1.5× avg)
3-mo avg 300.3K
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ENTA - Filings & News (Page 2)

ENTA
Jan 26, 2026, 4:05 PM EST
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $12.92
Real-time Price: $7.62 info
Change: -$5.30 (-41%) info
Market Cap: $222.19M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets